AI Stock Analysis - Bristol-Myers Squibb (BMY)
Analysis generated October 25, 2025.
Bristol Myers Squibb (BMY) is a global biopharmaceutical company that is dedicated to discovering, developing, and delivering innovative medicines to patients with serious diseases. The company operates in a highly competitive pharmaceutical industry, with a robust portfolio of treatments in areas such as oncology, immunology, cardiovascular, and fibrosis.
Stock Alerts - Bristol-Myers Squibb (BMY)
 |
Bristol-Myers Squibb | January 16 Julie Johnson (member of U.S. congress) is selling shares |
|
Bristol-Myers Squibb | January 14 Julia Letlow (member of U.S. congress) is buying shares |
|
Bristol-Myers Squibb | January 13 Gilbert Cisneros (member of U.S. congress) is buying shares |
|
Bristol-Myers Squibb | January 12 Job postings are down by 17.9% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Bristol-Myers Squibb
About Bristol-Myers Squibb
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
| Price | $55.56 |
| Target Price | Sign up |
| Volume | 11,330,000 |
| Market Cap | $111B |
| Year Range | $42.1 - $57.02 |
| Dividend Yield | 4.54% |
| PE Ratio | 18.38 |
| Analyst Rating | 33% buy |
| Earnings Date | February 5 '26 |
| Industry | Drug Manufacturers |
In the news
 |
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowJanuary 25 - Yahoo |
|
Camzyos Trial Win and Microsoft AI Lung Program Might Change The Case For Investing In BMYJanuary 23 - Yahoo |
|
Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline DevelopmentsJanuary 23 - Yahoo |
 |
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos ExpansionJanuary 22 - SeekingAlpha |
|
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial ResultsJanuary 22 - Yahoo |
|
JANX Enters Global Oncology Collaboration With BMY, Stock RisesJanuary 22 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 12.2B | 3.44B | 8.79B | 2.2B | 4.59B | 1.630 |
| Q2 '25 | 12.3B | 4.2B | 8.07B | 1.31B | 3.29B | 1.460 |
| Q1 '25 | 11.2B | 3.86B | 7.34B | 2.46B | 4.48B | 1.800 |
| Q4 '24 | 12.3B | 4.92B | 7.42B | 72M | 2.55B | 1.670 |
| Q3 '24 | 11.9B | 5.28B | 6.62B | 1.21B | 4.77B | 1.800 |
Insider Transactions View All
| Elkins David V filed to sell 167,379 shares at $47.3. September 3 '25 |
| Short Bartie Wendy filed to sell 5,066 shares at $44.2. August 5 '25 |
| Hirawat Samit filed to buy 83,513 shares at $47.6. April 29 '25 |
| BOERNER CHRISTOPHER S. filed to buy 104,626 shares at $55. February 21 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$224.44 1.3% | 44 |
 |
Eli Lilly and CompanyLLY |
$1039.51 2.2% | 62 |
 |
PfizerPFE |
$26.5 2.4% | 51 |
 |
AstrazenecaAZN |
$95.6 1.5% | 49 |
 |
AbbVieABBV |
$223.93 1.4% | 53 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julie Johnson |
Jan 16, 26 | Sell | $1K - $15K |
| Julia Letlow |
Jan 14, 26 | Sell | $1K - $15K |
| Julia Letlow |
Jan 14, 26 | Buy | $1K - $15K |
Read more about Bristol-Myers Squibb (BMY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Bristol-Myers Squibb
The Market Cap of Bristol-Myers Squibb is $111B.
As of today, Bristol-Myers Squibb's PE (Price to Earnings) ratio is 18.38.
Bristol-Myers Squibb will report its next earnings on February 5 '26.
Currently, the price of one share of Bristol-Myers Squibb stock is $55.56.
The BMY stock price chart above provides a comprehensive visual representation of Bristol-Myers Squibb's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bristol-Myers Squibb shares. Our platform offers an up-to-date BMY stock price chart, along with technical data analysis and alternative data insights.
Yes, Bristol-Myers Squibb (BMY) offers dividends to its shareholders, with a dividend yield of 4.54%. This dividend yield represents Bristol-Myers Squibb's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Bristol-Myers Squibb in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Bristol-Myers Squibb are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
